Retinal Vein Occlusion News and Research

RSS
Central retinal vein occlusion (CRVO) is the most common disease of the retinal vessels. It refers to a blockage of the vein draining the retinal tissue at the back of the eye. Occurring mostly in the elderly or middle-aged, it causes a subacute loss of vision.
AI-Doctor's accuracy in retinal disease detection redefines medical diagnosis

AI-Doctor's accuracy in retinal disease detection redefines medical diagnosis

The role of diet in the management of retinal vein occlusion

The role of diet in the management of retinal vein occlusion

UVA research provides new insight into common causes of vision loss

UVA research provides new insight into common causes of vision loss

Topical ocular administration of progesterone could be viable treatment for retinitis pigmentosa

Topical ocular administration of progesterone could be viable treatment for retinitis pigmentosa

Treatment for retinal vein occlusion yields long-lasting vision gains, study shows

Treatment for retinal vein occlusion yields long-lasting vision gains, study shows

COVID-19 patients' eyes and tears can be infected with SARS-CoV-2

COVID-19 patients' eyes and tears can be infected with SARS-CoV-2

AI could predict treatment demand for chronic eye diseases

AI could predict treatment demand for chronic eye diseases

New mobile app can help people diagnosed with glaucoma

New mobile app can help people diagnosed with glaucoma

New eye drops could prevent vision loss after retinal vein occlusion

New eye drops could prevent vision loss after retinal vein occlusion

RetiPharma secures funding to develop new peptide drug for treating degenerative eye disorders

RetiPharma secures funding to develop new peptide drug for treating degenerative eye disorders

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Saving sight of millions by making eye injections safe and comfortable

Saving sight of millions by making eye injections safe and comfortable

FDA approves marketing of AI device to detect diabetic retinopathy

FDA approves marketing of AI device to detect diabetic retinopathy

FDA authorizes marketing of first AI device to detect diabetic retinopathy

FDA authorizes marketing of first AI device to detect diabetic retinopathy

Study suggests potential means of stalling or even reversing diabetes-related blindness

Study suggests potential means of stalling or even reversing diabetes-related blindness

Largest clinical specialty database powers studies that yield key insights

Largest clinical specialty database powers studies that yield key insights

Two widely used drugs show effectiveness in treating patients with CRVO-associated macular edema

Two widely used drugs show effectiveness in treating patients with CRVO-associated macular edema

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

IQWiG examines added benefit of aflibercept in macular oedema after branch retinal vein occlusion

IQWiG examines added benefit of aflibercept in macular oedema after branch retinal vein occlusion

Bayer HealthCare, Johns Hopkins University to jointly develop new ophthalmic therapies targeting retinal diseases

Bayer HealthCare, Johns Hopkins University to jointly develop new ophthalmic therapies targeting retinal diseases

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.